Sudeep Pharma valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
Price multiples — at each FY-end close
67.67×—
13.33×—
17.99×—
Enterprise multiples
18.14×—
51.35×—
55.11×—
Yield
1.5%—
−0.4%—
Reference — adjusted share basis
₹1,130.10—
₹16.70₹15.31
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals
₹ CrorePeersSUDARSCHEMSTYRENIXSHARDACROPREFEXRCFRALLISRAINPRIVISCLMcap ₹12,764 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E—67.67
P/B—13.33
P/Sales—17.99
Enterprise Multiples
EV/Sales—18.14
EV/EBITDA—51.35
EV/EBIT—55.11
Yield
Earnings Yield %—1.48
FCF Yield %—-0.38
Reference — adjusted share basis
Price (FY-end close, adj.)—1,130.10
EPS (adj.)15.3116.70
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.